biostudies-literaturePalanisamy NNCINCI NIH HHSJanssen Research and Development NIH NCINIH NCI4933-4946https://www.ebi.ac.uk/biostudies/studies/S-EPMC7501166biostudies-literatureUnknown26(18)<h4>Purpose</h4>Advances in prostate cancer lag behind other tumor types partly due to the paucity of models reflecting key milestones in prostate cancer progression. Therefore, we develop clinically relevant prostate cancer models.<h4>Experimental design</h4>Since 1996, we have generated clinically annotated patient-derived xenografts (PDXs; the MDA PCa PDX series) linked to specific phenotypes reflecting all aspects of clinical prostate cancer.<h4>Results</h4>We studied two cell line-derived xenografts and the first 80 PDXs derived from 47 human prostate cancer donors. Of these, 47 PDXs derived from 22 donors are working models and can be expanded either as cell lines (MDA PCa 2a and 2b) or PDXs. The histopathologic, genomic, and molecular characteristics (androgen receptor, ERG, and <i>Clinical cancer research : an official journal of the American Association for Cancer ResearchThe MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.PMC7501166P30 CA016672P30CA16672U01 CA224044P50 CA140388Yang JBroom BMKunju LPPalanisamy NLogothetis CJPisters LLShepherd PDAManyam GCLi-Ning-Tapia EMWan XTomlins SANavone NMCarskadon SLChinnaiyan AMVazquez ESTroncoso PRavoori MKAparicio AMLabanca EEfstathiou EKundra VWang XAraujo JCfalseThe MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.<h4>Purpose</h4>Advances in prostate cancer lag behind other tumor types partly due to the paucity of models reflecting key milestones in prostate cancer progression. Therefore, we develop clinically relevant prostate cancer models.<h4>Experimental design</h4>Since 1996, we have generated clinically annotated patient-derived xenografts (PDXs; the MDA PCa PDX series) linked to specific phenotypes reflecting all aspects of clinical prostate cancer.<h4>Results</h4>We studied two cell line-derived xenografts and the first 80 PDXs derived from 47 human prostate cancer donors. Of these, 47 PDXs derived from 22 donors are working models and can be expanded either as cell lines (MDA PCa 2a and 2b) or PDXs. The histopathologic, genomic, and molecular characteristics (androgen receptor, ERG, and <i>2020-01-01T00:00:00Z2020 Sep2025-04-03T22:16:37.198Z2021-03-17T08:15:34ZS-EPMC75011663257662610.1158/1078-0432.CCR-20-047910.1158/1078-0432.ccr-20-0479